GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells

References

• Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, et al. Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA. Pediatr Res. 2017;82:527–535. https://doi.org/10.1038/pr.2017.74. PMID:28419087
   PubMed Web of Science ®Google Scholar
• Olsen RR, Otero JH, Garcia-Lopez J, Wallace K, Finkelstein D, Rehg JE, Yin Z, Wang YD, Freeman KW. MYCN induces neuroblastoma in primary neural crest cells. Oncogene. 2017;36:5075–5082. https://doi.org/10.1038/onc.2017.128
   PubMed Web of Science ®Google Scholar
• Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397-411. https://doi.org/10.1038/nrc3526. PMID:23702928
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106-20. https://doi.org/10.1016/S0140-6736(07)60983-0. PMID:17586306
   PubMed Web of Science ®Google Scholar
• Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078. https://doi.org/10.1038/nrdp.2016.78. PMID:27830764
   PubMed Web of Science ®Google Scholar
• Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt O, et al. Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell Death Dis. 2017;8:e2635. https://doi.org/10.1038/cddis.2017.49. PMID:28252645
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Guan S, Cao W, Wang H, Chen Z, Zhao Y, Yu Y, Zhang H, Pang JC, et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016;6:19423. https://doi.org/10.1038/srep19423. PMID:26786851
   PubMed Web of Science ®Google Scholar
• Westhoff MA, Faham N, Marx D, Nonnenmacher L, Jennewein C, Enzenmuller S, Gonzalez P, Fulda S, Debatin KM. Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One. 2013;8:e83128. https://doi.org/10.1371/journal.pone.0083128. PMID:24391739
   PubMed Web of Science ®Google Scholar
• Xie G, Wang Z, Chen Y, Zhang S, Feng L, Meng F, Yu Z. Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response. Cancer Lett. 2017;388:12-20. https://doi.org/10.1016/j.canlet.2016.11.024. PMID:27894954
   PubMed Web of Science ®Google Scholar
• Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, Fulda S. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer. 2013;132:2682-93. https://doi.org/10.1002/ijc.27935. PMID:23151917
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27:5511-26. https://doi.org/10.1038/onc.2008.246. PMID:18794885
   PubMed Web of Science ®Google Scholar
• Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 2010;24:1781-4. https://doi.org/10.1038/leu.2010.154. PMID:20703254
   PubMed Web of Science ®Google Scholar
• Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer. 2009;100:1267-76. https://doi.org/10.1038/sj.bjc.6604995. PMID:19319133
   PubMed Web of Science ®Google Scholar
• Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Redini F, Ory B, Heymann D. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2014;344:291-8. https://doi.org/10.1016/j.canlet.2013.11.017. PMID:24333720
   PubMed Web of Science ®Google Scholar
• Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69:6565-72. https://doi.org/10.1158/0008-5472.CAN-09-0913. PMID:19638577
   PubMed Web of Science ®Google Scholar
• Alao JP. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24. https://doi.org/10.1186/1476-4598-6-24. PMID:17407548
   PubMed Web of Science ®Google Scholar
• Moroy T, Geisen C. Cyclin E. Int J Biochem Cell Biol. 2004;36:1424-39. https://doi.org/10.1016/j.biocel.2003.12.005. PMID:15147722
   PubMed Web of Science ®Google Scholar
• Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GP. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 2002;62:2488-92. PMID:11980638
   PubMed Web of Science ®Google Scholar
• Liu HX, Ly I, Hu Y, Wan YJ. Retinoic acid regulates cell cycle genes and accelerates normal mouse liver regeneration. Biochem Pharmacol. 2014;91:256-65. https://doi.org/10.1016/j.bcp.2014.07.003. PMID:25087568
   PubMed Web of Science ®Google Scholar
• Daniel C C, Matthew B C, David J P, Michael Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVPBEZ235 Compared to Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2010;16:3628-38. https://doi.org/10.1158/1078-0432.CCR-09-3022. PMID:20606035
   PubMed Web of Science ®Google Scholar
• Duan Y, Tian L, Gao Q, Liang L, Zhang W, Yang Y, Zheng Y, Pan E, Li S, Tang N. Chromatin remodeling gene ARID2 targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression. Oncotarget. 2016;7:45863-75. https://doi.org/10.18632/oncotarget.10244. PMID:27351279
   PubMed Web of Science ®Google Scholar
• Zhang LD, Liu Z, Liu H, Ran DM, Guo JH, Jiang B, Wu YL, Gao FH. Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy. Int J Oncol. 2016;49:657-65. PMID:27278249
   PubMed Web of Science ®Google Scholar
• Gladden AB, Diehl JA. Cell cycle progression without cyclin E/CDK2: Breaking down the walls of dogma. Cancer Cell. 2003;4:160-2. https://doi.org/10.1016/S1535-6108(03)00217-4. PMID:14522248
   PubMed Web of Science ®Google Scholar
• Gwak H, Kim Y, An H, Dhanasekaran DN, Song YS. Metformin induces degradation of cyclin D1 via AMPK/GSK3beta axis in ovarian cancer. Mol Carcinog. 2017;56:349-58. https://doi.org/10.1002/mc.22498. PMID:27128966
   PubMed Web of Science ®Google Scholar
• Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853-7. https://doi.org/10.1038/sj.onc.1207721. PMID:15208673
   PubMed Web of Science ®Google Scholar
• Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS, Cheon J. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol. 2014;45:1027-35. https://doi.org/10.3892/ijo.2014.2505. PMID:24969552
   PubMed Web of Science ®Google Scholar
• Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway. Lab Invest. 2010;90:1406-14. https://doi.org/10.1038/labinvest.2010.133. PMID:20661228
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960-76. https://doi.org/10.1016/j.cell.2017.02.004. PMID:28283069
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang X, Geng L, Teng L, Legerski RJ. Artemis regulates cell cycle recovery from the S phase checkpoint by promoting degradation of cyclin E. J Biol Chem. 2009;284:18236-43. https://doi.org/10.1074/jbc.M109.002584. PMID:19423708
   PubMed Web of Science ®Google Scholar
• Mandal S, Freije WA, Guptan P, Banerjee U. Metabolic control of G1-S transition: cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system. J Cell Biol. 2010;188:473-9. https://doi.org/10.1083/jcb.200912024. PMID:20176921
   PubMed Web of Science ®Google Scholar
• Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem. 2000;275:22916-24. https://doi.org/10.1074/jbc.M002235200. PMID:10781597
   PubMed Web of Science ®Google Scholar
• Yang Y, Wu J, Cai J, He Z, Yuan J, Zhu X, Li Y, Li M, Guan H. PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells. Int J Cancer. 2015;136:E39-50. https://doi.org/10.1002/ijc.29150. PMID:25142862
   PubMed Web of Science ®Google Scholar
• Sukamporn P, Rojanapanthu P, Silva G, Zhang X, Gritsanapan W, Baek SJ. Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulation. Life Sci. 2016;152:60-6. https://doi.org/10.1016/j.lfs.2016.03.038. PMID:27018445
   PubMed Web of Science ®Google Scholar
• Barbash O, Egan E, Pontano LL, Kosak J, Diehl JA. Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation. Oncogene. 2009;28:4317-25. https://doi.org/10.1038/onc.2009.287. PMID:19767775
   PubMed Web of Science ®Google Scholar
• Yu XJ, Han QB, Wen ZS, Ma L, Gao J, Zhou GB. Gambogenic acid induces G1 arrest via GSK3beta-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett. 2012;322:185-94. https://doi.org/10.1016/j.canlet.2012.03.004. PMID:22410463
   PubMed Web of Science ®Google Scholar
• Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25:329-37. https://doi.org/10.1038/sj.onc.1209020. PMID:16421604
   PubMed Web of Science ®Google Scholar